Letrozole 1.5mg

Letrozole (commonly known by its brand name Femara) is an oral non-steroidal, competitive Type II Aromatase Inhibitor (AI). It is primarily prescribed as a first-line treatment for hormone receptor-positive breast cancer in postmenopausal women.

Among all aromatase inhibitors (including Anastrozole and Exemestane), Letrozole is recognized as the most potent. It targets and inhibits the aromatase enzyme—the enzyme responsible for converting androgens into estrogens—achieving near-complete suppression of circulating estradiol ($E_2$). In hormone management and performance contexts, a 1.5mg formulation serves as a strong dose designed to manage severe hyperestrogenism, reverse early-stage gynecomastia, or control heavy aromatization.

Key Benefits & Applications

• Maximum Estradiol Suppression: Capable of lowering circulating serum estrogen levels by up to 98%, providing the highest level of aromatase inhibition available in oral pharmacology.

• Gynecomastia Reversal / Control: Frequently utilized as a targeted intervention to arrest and potentially reverse early, non-fibrotic gynecomastia (breast tissue growth) caused by excessive aromatization.

• Elimination of Severe Water Retention: Rapidly reduces extracellular water retention, bloating, and elevated blood pressure associated with high circulating estradiol.

• HPTA Stimulation: By blocking central estrogenic negative feedback at the hypothalamus and pituitary, it can stimulate a surge in endogenous Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH).